Cryselle 28 Shortage: What Providers and Prescribers Need to Know in 2026

Provider Briefing: Cryselle 28 Availability in 2026

If your patients are reporting difficulty filling Cryselle 28 prescriptions, their frustration is well-founded. While norgestrel/ethinyl estradiol 0.3 mg/0.03 mg is not formally listed on the FDA drug shortage database, intermittent supply disruptions have made this combination oral contraceptive inconsistently available at retail pharmacies across the country.

This briefing covers the current supply landscape, prescribing considerations, therapeutic alternatives, and tools you can use to help patients maintain uninterrupted contraceptive coverage.

Timeline: How We Got Here

The availability issues with Cryselle 28 and its equivalents didn't emerge overnight. Here's the broader context:

• 2022–2023: The oral contraceptive market began experiencing broader supply instability as generic manufacturers consolidated operations and raw material supply chains faced post-pandemic pressures.
• 2024: Several generic oral contraceptive products saw intermittent stock-outs at retail pharmacies. The FDA reported an overall increase in drug shortage notifications, though most oral contraceptives were not formally listed.
• 2025–2026: Availability of specific norgestrel/ethinyl estradiol brands (including Cryselle 28, Elinest, and Low-Ogestrel) has fluctuated by region. Teva Pharmaceuticals, the primary manufacturer, has not declared a formal shortage, but wholesaler allocation limits have created localized gaps.

The pattern is consistent with what we see across the generic market: low-margin products from a small number of manufacturers are vulnerable to supply disruptions that don't meet the threshold for formal shortage designation but significantly impact patient access.

Prescribing Implications

For providers prescribing Cryselle 28, several considerations are relevant in the current environment:

Generic Substitution

Unless you write "dispense as written" (DAW), pharmacies can — and often will — substitute an AB-rated generic. For norgestrel/ethinyl estradiol 0.3 mg/0.03 mg, the interchangeable products include:

• Low-Ogestrel
• Elinest
• Turqoz

All four products (including Cryselle) are considered therapeutically equivalent by the FDA. However, some patients report subjective differences between brands, likely due to variations in inactive ingredients affecting absorption or tolerability. If a patient has a documented preference or adverse reaction history, DAW designation may be appropriate — but be aware this may make filling the prescription harder in the current supply environment.

When to Consider a Therapeutic Alternative

If all norgestrel/ethinyl estradiol products are unavailable, the following substitutions maintain the same mechanism of action (combined estrogen-progestin oral contraception) with comparable efficacy:

• Levonorgestrel 0.15 mg / ethinyl estradiol 0.03 mg (Levora, Portia, Altavera) — pharmacologically similar since levonorgestrel is the active enantiomer of norgestrel
• Norgestimate 0.25 mg / ethinyl estradiol 0.035 mg (Sprintec, Ortho-Cyclen) — less androgenic progestin, slightly higher estrogen dose
• Desogestrel 0.15 mg / ethinyl estradiol 0.03 mg (Apri, Desogen) — third-generation progestin, same estrogen dose

When switching a stable patient to a new formulation, document the clinical rationale and counsel the patient on potential adjustment symptoms (breakthrough bleeding, mood changes) for 2–3 cycles.

Current Availability Picture

The availability of Cryselle 28 varies significantly by region and pharmacy type:

• Chain pharmacies: CVS, Walgreens, and Rite Aid locations report inconsistent stock. These chains typically share wholesaler networks, so when one location is out, nearby chains often are too.
• Independent pharmacies: May have access to different wholesalers or secondary distributors and sometimes have stock when chains don't.
• Mail-order: Insurance plan mail-order pharmacies may have more consistent availability due to centralized procurement.
• Telehealth services: Online prescribing platforms (Nurx, SimpleHealth) that partner with mail-order pharmacies may offer an alternative fulfillment pathway.

Cost and Access Considerations

Under the ACA contraceptive coverage mandate, most insured patients should have access to at least one generic COC at $0 copay. However:

• Some plans may designate a different norgestrel/ethinyl estradiol brand as the preferred generic, creating a copay for Cryselle specifically
• Uninsured patients face cash prices of $30–$62 per pack — coupon programs (GoodRx, SingleCare) can reduce this to $12–$23
• The Teva Cares Foundation offers a patient assistance program for qualifying uninsured or underinsured patients (tevacares.org)

For uninsured patients, refer them to our guide on saving money on Cryselle 28 or the provider-focused savings guide at how to help patients save money on Cryselle 28.

Tools and Resources for Your Practice

Several tools can help you and your patients navigate availability challenges:

• Medfinder for Providers: Real-time pharmacy stock checking tool. Direct patients here or use it in your workflow to identify pharmacies with Cryselle 28 in stock before writing a prescription.
• FDA Drug Shortage Database: Monitor for formal shortage designations at accessdata.fda.gov/scripts/drugshortages
• ASHP Drug Shortage Resource Center: The American Society of Health-System Pharmacists maintains an additional shortage tracker at ashp.org
• State pharmacy boards: Some states have reporting mechanisms for localized shortage patterns

Looking Ahead

The generic oral contraceptive supply chain faces structural challenges that are unlikely to resolve quickly. Manufacturing consolidation, low profit margins, and complex regulatory requirements mean that intermittent availability issues may persist through 2026 and beyond.

Proactive prescribing — including documenting backup options in the chart, discussing alternative brands with patients before a shortage affects them, and leveraging real-time stock tools — can help minimize disruptions to patient care.

For a practical guide on integrating these strategies into your workflow, see our companion post: How to Help Your Patients Find Cryselle 28 in Stock.

Final Thoughts

Cryselle 28 availability in 2026 presents a manageable but persistent challenge. The key for providers is to anticipate supply issues, maintain awareness of equivalent and alternative products, and equip patients with tools to find their medication. By staying ahead of the supply curve, you can ensure that contraceptive access doesn't become a casualty of generic market economics.